Differential Expression Analysis and Transcriptomic Characterization of Glioma Progression
ISEF · 2021 Biomedical and Health Sciences Fourth Award
Overview
Gliomas make up nearly a third of all brain tumors and are extremely aggressive in later stages, with only a 5% five-year survival rate. Each year, approximately 20,000 people are diagnosed with glioma in the US. Publicly available RNA-Seq data was used to identify differentially expressed genes (DEGs) and survival analysis was performed to validate their effects on patient prognosis. Gene expression levels were compared between varying grades of glioma and to normal brain samples. 41 out of the top 100 most significant DEGs were associated with increased patient mortality. Analysis showed glioma progression is strongly correlated with increases in expression of SAA1, PLA2G2A, and H19 genes over 17-fold (hazard ratio of 15); and decreases in expression of HPSE2, SELL, and SFRP2 genes over 4-fold (hazard ratio of 12). Expression levels of these genes could potentially act as biomarkers for screening tests. Samples were then grouped by the presence or absence of mutations and methylation, and analyzed using Gene Set Enrichment Analysis. Results showed positive enrichment of G2/M cell cycle checkpoint genes, E2F transcription factors, and MYC gene sets across all groups. Normalized enrichment scores were similar across all groups, indicating the presence of mutations and methylation do not have large impacts on patterns of gene expression. Pathway analysis showed retinoic acid receptor signaling and ribosome assembly are heavily upregulated throughout the entirety of glioma progression in all patients, making these pathways attractive targets for interventions in future studies and drug development.
Awards (2)
- Fourth Award of $500 $500
- American Statistical Association: Certificate of Honorable Mention
Competition history
- ISEF 2021
Resources
Related projects
ISEF · 2019
An in silico Analysis of Glioblastoma Patients for the Identification of a miRNA Signature as a Diagnostic Biomarker
ISEF · 2021
Comparative Analysis of Genetic Mutations and Overall Survival in Patients with Glioblastoma Multiforme: A Retrospective Cohort Study
ISEF · 2024
The Effect of Somatic Mutations in Glioblastoma Multiforme on Patient Survival
ISEF · 2021
Intratumoral Heterogeneity in Gene Expression within Single Glioblastoma Tumors
ISEF · 2022
Evolution of Oncogenic Signatures Within Glioblastoma Along a Spatiotemporal Axis
ISEF · 2014
Progressing Targeted Cancer Therapy and Diagnosis: Analyzing the Role of MiRNA Target Interactions and Expression Signatures for Glioblastoma Progression
ISEF · 2018
Computational Analyses to Identify Genes Disproportionately Affected by NFKBIA Deletions and Implicated in Breast Cancer and Glioblastoma Tumorigenesis
ISEF · 2017
Characterization of Patient-Derived Glioblastoma Cell Lines
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: Regeneron International Science and Engineering Fair